Published September 17, 2021
| Version v1
Journal article
Open
Postnatal immune activation causes social deficits in a mouse model of tuberous sclerosis: Role of microglia and clinical implications
Creators
-
López-Aranda, Manuel F.1
-
Chattopadhyay, Ishanu2
-
Boxx, Gayle M.1
- Fraley, Elizabeth R.1
-
Silva, Tawnie K.1
-
Zhou, Miou1
- Phan, Miranda1
-
Herrera, Isaiah1
-
Taloma, Sunrae1
-
Mandanas, Rochelle1
-
Bach, Karen1
-
Gandal, Michael1
-
Geschwind, Daniel H.1
-
Cheng, Genhong1
-
Rzhetsky, Andrey2
-
White, Stephanie A.1
-
Silva, Alcino J.1
- 1. University of California, Los Angeles
- 2. University of Chicago
Description
There is growing evidence that prenatal immune activation contributes to neuropsychiatric disorders. Here, we show that early postnatal immune activation resulted in profound impairments in social behavior, including in social memory in adult male mice heterozygous for a gene responsible for tuberous sclerosis complex (Tsc2+/−), a genetic disorder with high prevalence of autism. Early postnatal immune activation did not affect either wild-type or female Tsc2+/− mice. We demonstrate that these memory deficits are caused by abnormal mammalian target of rapamycin–dependent interferon signaling and impairments in microglia function. By mining the medical records of more than 3 million children followed from birth, we show that the prevalence of hospitalizations due to infections in males (but not in females) is associated with future development of autism spectrum disorders (ASD). Together, our results suggest the importance of synergistic interactions between strong early postnatal immune activation and mutations associated with ASD.
Data availability
PLX5622 was obtained under a material transfer agreement with Plexxikon. All data needed to evaluate the conclusions in the paper are present in the paper and/or the Supplementary Materials.Files
sciadv.abf2073.pdf
Files
(10.5 MB)
| Name | Size | Download all |
|---|---|---|
|
Article md5:a0e55eea492509e88114400d210380d3 |
1.4 MB | Preview Download |
|
md5:d24d64ecb66cc151b8f14681c9780261
|
9.1 MB | Preview Download |
Additional details
Identifiers
- DOI
- 10.1126/sciadv.abf2073
- Other
- oai:uchicago.tind.io:11071
Funding
- Children's Tumor Foundation
- 2014-01-014
- Human Frontier Science Program
- LT000822/2011-L
- National Institute of Mental Health
- R01 MH084315
- Takeda Pharmaceutical Company Limited